TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02059187
Drug: Lantus™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lantus™ (insulin glargine \[rDNA origin\]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study: NCT01935531
Drug: 3% diclofenac in 2.5% hyaluronic acid gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01090713
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-70mg; oral
Study: NCT00190944
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00848003
Drug: Bifidobacterium animalis subsp. lactis strain BB-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
Study: NCT00848003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored yogurt
Study: NCT01489371
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04309474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT00063193
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00063193
Drug: creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02717754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir matched placebo will be administered intravenous for 5 days.
Study: NCT01200238
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00679055
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
Study: NCT02920424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo.
Study: NCT03101579
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
Study: NCT00528879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
Study: NCT00644605
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Study: NCT02605083
Drug: eFT508
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given orally once or twice daily. Each treatment cycle = 21 days.
Study: NCT01873703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01081483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description for more information
Study: NCT00267293
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given for fever control 15mg/kg
Study: NCT00267293
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given for fever control 10 mg/kg
Study: NCT02934269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01269788
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Study: NCT01269788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral , daily 30 mins before breakfast, for 6 weeks
Study: NCT04382157
Drug: Mablet 360 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-released magnesium hydroxide
Study: NCT01850303
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of carboplatin-paclitaxel
Study: NCT00878449
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study: NCT03364985
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 tablets
Study: NCT03364985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets
Study: NCT04699643
Drug: EVER4010001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please refer to information in arm/group descriptions.
Study: NCT02420899
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/d or 20mg/d,po
Study: NCT00459082
Drug: Dexmedetomine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01168882
Drug: RGB-286638
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
Study: NCT01682473
Drug: ZSTK474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two arms, each with serial cohorts receiving escalating doses.
Study: NCT00637442
Drug: Reminyl retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
Study: NCT02174900
Drug: Artemether-Lumefantrine (AL) combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02315443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00404586
Drug: GW784568X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
Study: NCT00404586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to GW784568X as aqueous nasal spray.
Study: NCT03292783
Drug: NOV1501 (ABL001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF/DLL4 targeting bispecific antibody
Study: NCT04260802
Drug: OC-001
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00781820
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
Study: NCT04304781
Drug: KSP/QRH dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
Study: NCT04687813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a tablet with the same appearance as FTP-198
Study: NCT04010539
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
Study: NCT00249288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken as 2, 1mg capsule daily for 12 weeks
Study: NCT02431247
Drug: DRV/COBI FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
Study: NCT02431247
Drug: FTC/TDF FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
Study: NCT02431247
Drug: D/C/F/TAF FDC - Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of D/C/F/TAF FDC will be administered once daily.
Study: NCT02112422
Drug: Intervention
Normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
Study: NCT02431247
Drug: FTC/TDF FDC Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of FTC/TDF FDC will be administered once daily.
Study: NCT02431247
Drug: DRV/COBI FDC Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of DRV/COBI FDC will be administered once daily.
Study: NCT04464564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT03550794
Drug: Thiamine Hydrochloride
Normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
Study: NCT03550794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50ml of 0.9% NACL will serve as the placebo
Study: NCT04630366
Drug: NST-1024
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: NST-1024
Study: NCT04630366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to NST-1024
Study: NCT03060031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Study: NCT02609997
Drug: proparacaine
Normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% proparacaine (Alcaine, Alcon Laboratories)
Study: NCT01884116
Drug: NSAID patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01884116
Drug: NSAID patch + heating pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Study: NCT03354156
Drug: statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
Study: NCT00283686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Study: NCT00457964
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 and 10 mg/day or 30, 50, 70mg/week
Study: NCT04034199
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
Study: NCT03001011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00990028
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral, for 10 days
Study: NCT00990028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vehicle
Study: NCT00575328
Drug: Maca Root
Normalized name: maca root
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g/day of Maca Root for 12 weeks.
Study: NCT05999942
Drug: Liposomal Amikacin for Inhalation
Normalized name: amikacin liposomal Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via the Pari LC STAR™ nebulizer.
Study: NCT00575328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study: NCT01493726
Drug: ALKS 9072, Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection, given monthly
Study: NCT01493726
Drug: ALKS 9072, High dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection, given monthly
Study: NCT01493726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed matched placebo IM injection, given monthly
Study: NCT02383589
Drug: Mycophenolate Mofetil Placebo
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF matching placebo will be administered orally Q12H.
Study: NCT00376584
Drug: MK-0524A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04726007
Drug: Antithrombotic Agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
Study: NCT00591825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01030367
Drug: PETN, ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
Study: NCT02070471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02070471
Drug: LC28-0126 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 Dose A
Study: NCT02070471
Drug: LC28-0126 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 Dose B
Study: NCT03523000
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Study: NCT03523000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Study: NCT01802489
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01802489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule identical in appearance to Amiloride 10mg capsule
Study: NCT00186264
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00450775
Drug: Dermatix Q
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatix Q applied twice daily
Study: NCT01469988
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
Study: NCT00003985
Drug: KRN7000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03472833
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
Study: NCT02600598
Drug: LEO 43204 Gel, 0.037%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02122510
Drug: Bupivacine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
Study: NCT04322968
Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
Study: NCT02755545
Drug: Product A
Normalized name: Vaccine product against severe acute respiratory syndrome coronavirus 2 (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product A applied topically to the entire face or other affected area of the skin once daily
Study: NCT02755545
Drug: Product B
Normalized name: Product base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product B applied topically to affected area of the skin 1 to 3 times daily
Study: NCT02815774
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: all subjects were given SP2086 50mg only one time.
Study: NCT01716754
Drug: QGE031
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL
Study: NCT01716754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
Study: NCT01389856
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
Study: NCT03640312
Drug: QUARTET LDQT
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
Study: NCT00206219
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03167177
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03167177
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03167177
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT03764553
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO Capecitabine
Study: NCT02716246
Drug: Prophylactic Immunomodulatory (IM) Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02716246
Drug: Optimized Prophylactic IM Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02716246
Drug: Adjuvant IM Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
Study: NCT01918722
Drug: ICH-1(herbal medicine with Hirudo, Tabanus)
Normalized name: TABANUS NIGROVITTATUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Study: NCT01918722
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo herbal medicine, one dose,bid, for 10 days
Study: NCT01918722
Drug: ICH-2(herbal medicine without Hirudo, Tabanus)
Normalized name: TABANUS NIGROVITTATUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Study: NCT00076024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg twice daily \[bid\] continuous dosing
Study: NCT03764553
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Leucovorin
Study: NCT02593734
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral drug therapy for depression
Study: NCT00902161
Drug: MK0893
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MK0893 1000 mg (ten 100 mg tablets)
Study: NCT00902161
Drug: MK0893-matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to MK0893 (ten tablets)
Study: NCT00301821
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00301821
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00195871
Drug: Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: coventional dosages
Study: NCT02931591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00121836
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
Study: NCT03447184
Drug: Androgen priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor
Study: NCT02172170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00048711
Drug: N-acetylgalactosamine 4-sulfatase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01386112
Drug: EUR-1100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oral medication
Study: NCT01386112
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01545843
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-40 mg fluoxetine daily for 8 weeks
Study: NCT04997590
Drug: Staphylococcal Enterotoxin C
Normalized name: Staphylococcal enterotoxin C specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.